메뉴 건너뛰기




Volumn 30, Issue 27, 2012, Pages 3426-3427

Before we throw out progression-free survival as a valid end point...

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

EID: 84866770750     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.1220     Document Type: Letter
Times cited : (7)

References (8)
  • 1
    • 84860496547 scopus 로고    scopus 로고
    • Progression-free survival: Meaningful or simply measurable?
    • Booth CM, Eisenhauer EA: Progression-free survival: Meaningful or simply measurable? J Clin Oncol 30:1030-1033, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 1030-1033
    • Booth, C.M.1    Eisenhauer, E.A.2
  • 2
    • 0027487289 scopus 로고
    • Importance of continued testicular suppression in hormone-refractory prostate cancer
    • Taylor CD, Elson P, Trump DL: Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11:2167-2172, 1993 (Pubitemid 23332253)
    • (1993) Journal of Clinical Oncology , vol.11 , Issue.11 , pp. 2167-2172
    • Taylor, C.D.1    Elson, P.2    Trump, D.L.3
  • 4
    • 71549143528 scopus 로고    scopus 로고
    • Detecting an overall survival benefit that is derived from progression-free survival
    • Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649, 2009
    • (2009) J Natl Cancer Inst , vol.101 , pp. 1642-1649
    • Broglio, K.R.1    Berry, D.A.2
  • 5
    • 0347600563 scopus 로고    scopus 로고
    • Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program
    • Shah NT, Miller VA: Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program. Clin Lung Cancer 5:182-186, 2003 (Pubitemid 38028809)
    • (2003) Clinical Lung Cancer , vol.5 , Issue.3 , pp. 182-186
    • Shah, N.T.1    Miller, V.A.2
  • 6
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
    • (2010) N Engl J Med , vol.363 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, D.R.3
  • 7
    • 77955877759 scopus 로고    scopus 로고
    • Early palliative care for patients with metastatic non-small-cell lung cancer
    • Temel JS, Greer JA, Muzikansky A, et al: Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733-742, 2010
    • (2010) N Engl J Med , vol.363 , pp. 733-742
    • Temel, J.S.1    Greer, J.A.2    Muzikansky, A.3
  • 8
    • 78149240696 scopus 로고    scopus 로고
    • Randomized phase II trials: Misleading and unreliable
    • Stewart DJ: Randomized phase II trials: Misleading and unreliable. J Clin Oncol 28:e649-e650, 2010
    • (2010) J Clin Oncol , vol.28
    • Stewart, D.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.